Lab Module 16

Question 1

Which type of bacteria is this (as displayed in the video) and can they tolerate oxygen?

A) Anaerobic, cannot tolerate oxygen
B) Aerobe, cannot tolerate oxygen
C) Aerobe, can tolerate oxygen
D) Anaerobic, can tolerate oxygen

Answer 1

Correct Answer:
A) Anaerobic, cannot tolerate oxygen

Question 2

This step is used to (BLANK).

A) Dilute the antigen
B) Create more T CELLS
C) Create more B CELLS
D) Concentrate the antigen

Answer 2

Correct Answer:
D) Concentrate the antigen

Question 3

Within this lab, (BLANK) cells lines are used here for (BLANK) viral antigens.

A) 20, 50
B) 50, 20
C) 50, 1,000
D) 100, 50

Answer 3

Correct Answer:
A) 20, 50

Question 4

Approximately how many doses of vaccine are made here at this plant each year?

A) 500
B) 500 million
C) 1 billion
D) 1,100

Answer 4

Correct Answer:
C) 1 billion

Question 5

This drying allows long term storage.

A) True
B) False

Answer 5

Correct Answer:
A) True

Question 6

Which of the following is not one of the steps in vaccine production?

A) Packing & labeling
B) Final vaccine production
C) Antigen production
D) Macrophage production

Answer 6

Correct Answer:
D) Macrophage production

Question 7

(BLANK) of the viruses made in St Joseph are human pathogens.

A) Five
B) One
C) Three
D) Six

Answer 7

Correct Answer:
C) Three

Question 8

How do countries without robust regulatory infrastructure typically handle vaccine safety oversight?

A) They avoid using vaccines until their own regulations are developed
B) They manufacture vaccines without any external standards
C) They rely solely on local pharmaceutical companies for regulation
D) They follow international recommendations from organizations like WHO, FDA, or EMA

Answer 8

Correct Answer:
D) They follow international recommendations from organizations like WHO, FDA, or EMA

Question 9

Which statement best reflects the typical timeline for vaccine development as described in the passage?

A) Vaccine development usually takes several decades due to regulatory delays.
B) Most vaccines are developed and approved within 1–2 years.
C) The development timeline is standardized worldwide at exactly 12 years.
D) The full process generally spans months to years, with an average of 10–15 years.

Answer 9

Correct Answer:
D) The full process generally spans months to years, with an average of 10–15 years.

Question 10

Why was cowpox exposure important in the development of the first smallpox vaccine?

A) Cowpox was used as a laboratory medium to grow smallpox virus.
B) Cowpox caused smallpox in a less severe form, which allowed for natural immunity.
C) Cowpox and smallpox were later found to be caused by the same virus.
D) Exposure to cowpox provided immunity against smallpox even before the causative agent was identified.

Answer 10

Correct Answer:
D) Exposure to cowpox provided immunity against smallpox even before the causative agent was identified.

Question 11

How has mRNA vaccine technology changed the process of developing vaccines once the causative agent is identified?

A) It can replicate any disease in animal models without laboratory testing.
B) It allows scientists to develop vaccines using only the genetic code of the pathogen.
C) It eliminates the need to identify the causative agent entirely.
D) It requires the entire pathogen to be cultured and inactivated before use.

Answer 11

Correct Answer:
B) It allows scientists to develop vaccines using only the genetic code of the pathogen.

Question 12

Which statement best distinguishes Phase II vaccine trials from Phase I trials?

A) Phase II trials do not include any placebo groups, unlike Phase I.
B) Phase II trials are always open-label, while Phase I trials are double-blind.
C) Phase II trials use fewer participants than Phase I trials.
D) Phase II trials are randomized and controlled, focusing on dose, timing, safety, and efficacy, whereas Phase I primarily assesses safety in a small group.

Answer 12

Correct Answer:
D) Phase II trials are randomized and controlled, focusing on dose, timing, safety, and efficacy, whereas Phase I primarily assesses safety in a small group.